Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevance
Authors:
- Melissa L PerreaultMPMelissa L Perreault
- Ahmed HasbiAHAhmed Hasbi
- Brian F O'DowdBOBrian F O'Dowd
- Susan R GeorgeSGSusan R George
- 18 June 2013
- journal article
- review article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 39 (1) , 156-168
Abstract
The pharmacological modification of dopamine transmission has long been employed as a therapeutic tool in the treatment of many mental health disorders. However, as many of the pharmacotherapies today are not without significant side effects, or they alleviate only a particular subset of symptoms, the identification of novel therapeutic targets is imperative. In light of these challenges, the recognition that dopamine receptors can form heteromers has significantly expanded the range of physiologically relevant signaling complexes as well as potential drug targets. Furthermore, as the physiology and disease relevance of these receptor heteromers is further understood, their ability to exhibit pharmacological and functional properties distinct from their constituent receptors, or modulate the function of endogenous homomeric receptor complexes, may allow for the development of alternate therapeutic strategies and provide new avenues for drug design. In this review, we describe the emerging neurobiology of the known dopamine receptor heteromers, their physiological relevance in brain, and discuss the potential role of these receptor complexes in neuropsychiatric disease. We highlight their value as targets for future drug development and discuss innovative research strategies designed to selectively target these dopamine receptor heteromers in the search for novel and clinically efficacious pharmacotherapies.Keywords
This publication has 130 references indexed in Scilit:
- Adenosine hypothesis of schizophrenia – Opportunities for pharmacotherapyNeuropharmacology, 2012
- Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptorsNeuropharmacology, 2011
- Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-TicEuropean Journal of Medicinal Chemistry, 2011
- Signaling pathways in schizophrenia: emerging targets and therapeutic strategiesTrends in Pharmacological Sciences, 2010
- Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanismsCurrent Opinion in Pharmacology, 2010
- Activation of calcium/calmodulin-dependent protein kinase IIα in the striatum by the heteromeric D1-D2 dopamine receptor complexNeuroscience, 2010
- Tropomyosin-Related Kinase B in the Mesolimbic Dopamine System: Region-Specific Effects on Cocaine RewardBiological Psychiatry, 2009
- Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal functionNeuropharmacology, 2008
- How and why do GPCRs dimerize?Trends in Pharmacological Sciences, 2008
- Neurotransmitter receptor heteromers and their integrative role in ‘local modules’: The striatal spine moduleBrain Research Reviews, 2007